Phaseline

Companies › Shenzhen Celconta Life Science

Shenzhen Celconta Life Science: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PANK-003 cell injection
Peripheral blood-derived allogeneic natural killer cells
–Phase 1Solid Tumors, AdultJan 2027
XKDCT225
anti-CLDN18.2 CAR-T cell therapy
–Phase 1Claudin18.2 Positive Advanced Solid TumorsJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06897228PANK-003 cell injectionPhase 1Solid Tumors, AdultOncologyJan 2027
NCT06782425XKDCT225Phase 1Claudin18.2 Positive Advanced Solid TumorsOncologyJan 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.